{"organizations": [], "uuid": "9e59f881e78204c49e2f98b7a0f1c969f7ca4a8c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/29/globe-newswire-akers-biosciences-announces-a-change-to-the-board-of-directors.html", "country": "US", "domain_rank": 767, "title": "Akers Biosciences Announces a Change to the Board of Directors", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-05-29T15:00:00.000+03:00", "replies_count": 0, "uuid": "9e59f881e78204c49e2f98b7a0f1c969f7ca4a8c"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/29/globe-newswire-akers-biosciences-announces-a-change-to-the-board-of-directors.html", "ord_in_thread": 0, "title": "Akers Biosciences Announces a Change to the Board of Directors", "locations": [], "entities": {"persons": [{"name": "john j. gormally", "sentiment": "none"}, {"name": "ben simons", "sentiment": "none"}, {"name": "raymond f. akers jr.", "sentiment": "none"}, {"name": "fiona henson", "sentiment": "none"}, {"name": "akers bio", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "thorofare", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "akers biosciences", "sentiment": "negative"}, {"name": "akers biosciences, inc.", "sentiment": "neutral"}, {"name": "securities and exchange commission", "sentiment": "none"}, {"name": "company", "sentiment": "none"}, {"name": "akers biosciences, inc", "sentiment": "none"}, {"name": "vigo communications", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "THOROFARE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the \"Company\"), a developer of rapid health information technologies, announces that Raymond F. Akers Jr., Ph.D has resigned as a director of the Company with immediate effect.\nPursuant to U.S. Federal Securities Laws, within four business days the Company will file a Form 8-K with the Securities and Exchange Commission, which may include further information with respect to the resignation.\nFor more information:\nAkers Biosciences, Inc.\nJohn J. Gormally, Chief Executive Officer\nTel. +1 856 848 8698\nVigo Communications (Global Public Relations)\nBen Simons / Fiona Henson\nTel. +44 (0)20 7830 9704\nEmail: akers@vigocomms.com\nAbout Akers Biosciences, Inc.\nAkers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.\nAdditional information on the Company and its products can be found at www.akersbio.com . Follow us on Twitter @AkersBio .\nCautionary Statement Regarding Forward Looking Statements\nStatements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. The include statements or expectations regarding the effects on the Company due to the resignation of Raymond F. Akers Jr., Ph.D from the Board of the Company, other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission and other future events. When used herein, the words \"anticipate,\" \"believe,\" \"estimate,\" \"upcoming,\" \"plan,\" \"target\", \"intend\" and \"expect\" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such . These are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to those expressed in, or implied by, these .\nSource:Akers Biosciences Inc", "external_links": ["https://www.globenewswire.com/Tracker?data=UTgh7NAlLZVbzGhci2H-B5cDypP74uB2mkxj4B4MlzVIy0soMmpdAByZ4wPTtEUmCJVLF723Vy1jVeq1bm2rog==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/666486c7-d84f-47de-9a79-619536d7019f", "https://www.globenewswire.com/Tracker?data=_Tc7hvLBgarUH0ajiXFZMGziAdPjwA7K47DiK4dpIpmbdJzqN2aG0wO__RfQ7KWfdgsjXbkNltZlzlKoufAawW6EpH2U5ReqsmWN6iSk0O8=", "https://www.globenewswire.com/Tracker?data=SfWfGvOhxq6jHKWvbsIv1CzaDoKsrpJ4PUmBXJPk1YrrObOeZNTN585J85Qcu-4BTHLFkR0vOUfoKg5a6BkEBg=="], "published": "2018-05-29T15:00:00.000+03:00", "crawled": "2018-05-29T16:30:35.003+03:00", "highlightTitle": ""}